Dr. Massimo Morfini

After graduating as a specialist in diseases of the digestive system and blood in 1973, he served as Assistant and then as Senior Registrar at the Hemophilia Center of the Hematology Department of the University Hospital of Florence, Italy. In 1999, he was appointed Coordinator of the Inherited Bleeding Disorders Reference Center of Tuscany. In 2004, he was appointed as Director of HC,  and moved to the Emergency Department. He was retired at the end of 2013.

He was a member of the Medical Advisory Board of the World Federation of Hemophilia (WFH), of the Editorial Board of JTH, and Co-chair of SSC FVIII/IX of ISTH. From 1986 to 2011, he was Vice-President of AICE, then President until the end of 2014. He has been a reviewer  for the following journals: Blood, JTH, TH, Blood Transfusion, Blood and Fibrinolysis, Transfusion, and Haemophilia.

So far, he has published 204 papers in peer reviewed journals.

Key Publications

1.       Morfini M. Innovative approach for improved rFVIII concentrate. Eur J Haematol. 2014 Apr 26

2.       Morfini M, Batorova A, Mariani G, Auerswald G, Bernardi F, Di Minno G, Dolce A, Fede C, Giansily-Blaizot M, Ingerslev J, Martinowitz U, Napolitano M, Pinotti M, Schved JF; for the International FVII [IF7] and Seven Treatment Evaluation Registry [STER] Study Groups. Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. Thromb Haemost. 2014 Apr 24;112(2)

3.       Hassan HJ, Morfini M, Taruscio D, Abbonizio F, Giampaolo A, Kodra Y, Oliovecchio E, Vittozzi L. Current status of Italian Registries on inherited bleeding disorders. Blood Transfus. 2014 Apr;12 Suppl 3:s576-81

4.       Morfini M, Coppola A, Franchini M, Di Minno G. Clinical use of factor VIII and factor IX concentrates Blood Transfus. 2013 Sep;11 Suppl 4:s55-63.

5.       Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, Jacobs I, Morfini M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012 Sep 20;120(12):2405-11.

Current Positions/Chairs:

  • President
    Italian Association of Hemophilia centers (AICE)

Key Institutions

  • Hemophilia Comprehensive Care Center of Florence University
    Florence, Italy

Research Interests

  • Hemophilic arthropathy by means of joint photoscin¬tigrafy with 99mTc
  • Platelet and coagulation alterations in myeloprolipherative disorders
  • Pharmacokinetics of Factor VIII or IX concentrates in hemophili¬acs, particularly as far as virus-inactivated concentrates are con¬cerned
  • Hepatitis safety of clotting factor concentrates, untreated or treated
  • Human Parvovirus B19 in hemophiliacs, in particular the transmission of B19 by virus-inactivated clotting factor concentrates in PUPs
  • Treatment of acquired or inherited bleeding disorders
  • Treatment of patient with FVIII/IX inhibitors, undergoing elective surgery
  • Immune-tolerance induction in haemophilia patients with FVIII/IX inhibitors
  • PK analysis of regular FVIII/IX concentrates and new long acting ones


  • Winner of two Bayer Awards